Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients | Science

Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti–PD-1 (programmed cell death protein 1) immunotherapy …
Source : ScienceMag